Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
Health and personal care products
Bought by French pharmaceuticals and vaccine giant, Sanofi, in 2010.
| Sanofi SA
owns 100% of Chattem Inc
This company has reported to the state of California that some of their products contain a known carcinogen or reproductive toxin, but they have requested trade secret status for these ingredients so that they are not publicly revealed.
Source: Women's Voices for the Earth (2014)
In 2021, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of A.
Source: CDP (2021)
In 2021, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of A.
Source: CDP (2021)
This company received an S&P Global ESG Score of 84/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 7 Feb 2021). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2021)
This company is listed as having best practice on a report card on lesbian, gay, bisexual and transgender equality in corporate America.
Source: Human Rights Campaign (2021)
The 2022 Global 100 Most Sustainable Corporations in the World list is based on a rigorous assessment of nearly 7,000 public companies with revenue over US$1 billion. All companies are scored on environmental, social, governance and economic metrics relative to their peers, with 50% of the weight assigned to Clean Revenue and Clean Investment. This company ranked #67 in the Global 100, with an overall score of C+.
Source: Corporate Knights (2022)
This company received a score of 7.8/100 (retrieved 10-Oct-2020) in the Corporate Information Transparency Index (CITI), a system for evaluating supply chain practices in China, particularly in regards to environmental management and water pollution. Scores are calculated using government compliance data, online monitoring data, and third-party environmental audits, as well as trends in the environmental performance of factories in the company's supply chains.
Source: IPE (2020)
As You Sow's 2019 report, Mining the Disclosures, is a deep analysis of 215 companies' human rights performance in relation to sourcing conflict minerals from the Democratic Republic of the Congo (DRC). This company's score was 3.9% (Weak).
Source: As You Sow (2019)
In 2019 several pharmaceutical companies finally settled a 2005 lawsuit which claimed the companies fudged wholesale drug prices to increase Medicaid reimbursements. In all, the state of Illinois received a combined $648 million over the course of that litigation. A subsidiary of this company was involved in the 2019 settlement.
Source: news article (2019)
In 2020 an American subsidiary of this company agreed to pay US$11.85 million to resolve allegations that it violated the False Claims Act by paying kickbacks to Medicare patients through a purportedly independent charitable foundation, The Assistance Fund.
Source: US Dept of Justice (2020)
In 2017 an American subsidiary of this company agreed to pay US$19.87 million to resolve claims that it incorrectly calculated drug prices and thereby overcharged the US Department of Veterans Affairs for drugs under two contracts between 2002 and 2011.
Source: US Dept of Justice (2017)
On 4 Sept 2018 the U.S. Securities & Exchange Commission announced that Sanofi agreed to pay more than $25 million to resolve charges that its Kazakhstan and the Middle East subsidiaries made corrupt payments to win business. According to the SEC's order, the schemes spanned multiple countries and involved bribe payments to government procurement officials and healthcare providers in order to be awarded tenders and to increase prescriptions of its products.
Source: US SEC (2018)
This company received a score of 49.9/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2017)
Changing Markets' 2016 report, 'Superbugs in the Supply Chain' investigates how pollution from antibiotics factories in India and China is fuelling the global rise of drug-resistant infections. "Sanofi has links to dirty production via its Czech subsidiary Zentiva, which sources the antibiotic Ciprofloxacin from Neuland Pharmaceuticals - an Indian pharma company that has been implicated in unlawful manufacturing discharges."
Source: Changing Markets (2016)
In June 2015, Sanofi's Indian subsidiary was fined US$9.4m by the Indian Competition Commission for colluding and forming a cartel (with GlaxoSmithKline) in their bidding practices to get government contracts for the supply of a meningitis vaccine. The vaccine was for use among 200,000 pilgrims visiting Mecca.
Source: Fierce Pharma (2015)
The Court of Appeals of Paris upheld a 40.6m euro antitrust fine against this company for campaigning to discourage doctors and pharmacists from prescribing or substituting a generic version of its blood thinner Plavix. The Court rejected this company's appeal of a May 2013 decision by the French Competition Authority and fining it for abusing its dominance and using a 'strategy of denigration' against generic Plavix competitors in 2009 and 2010. [Listed under Information due to age of court finding]
Source: Law 360 (2014)
This company was fined 28m euros because two of its former employees were convicted of bribery by a German court in December 2013. The former employees had made illicit payments to a consultancy advising one of this company's clients between 2007 and 2010 to win new orders for the client. This led to Sanofi being unfairly given preference. [Listed under Information due to age of court finding]
Source: news article (2014)
This company is one of the pharmaceutical companies using free 'health camps' in India to test poor patients for diseases and then prescribe them drugs. In violation of the regulations of the Medical Council of India, the camps often do not have licensed doctors but use drug sales representatives to undertake health checks.
Source: British Medical Journal (2015)
Azmacort, Nasacort and Nasacort AQ are all steroid-based anti-inflammatory nasal sprays used to treat nasal congestion during the onset of a sinus infection, the common cold or hay fever. Their manufacturer, Aventis Pharmaceutical, which is a subsidiary of Sanofi-Aventis, agreed to $95.5 million in fines in 2009 after the company was found to have misreported the drugs' best prices, thereby avoiding paying millions of dollars in rebates to Medicaid between 1995 and 2000. [Listed under Information due to age of court finding]
Source: Drug Watch (2009)
In 2012, the US Department of Justice announced that this company agreed to pay US$109m to resolve allegations that they violated the False Claims Act by giving doctors free samples of knee injection product Hylagan to encourage them to buy and prescribe the treatment. The settlement also resolved allegations that the company submitted false sales reports for Hylagan that did not account for the free samples distributed contingent on purchases of the product. [Listed under Information due to age of court finding]
Source: First Word Pharma (2012)
Sanofi-Aventis has been investigated by USA's Food and Drug Administration for supplying the agency with fraudulent clinical trial data. Sanofi has run into legal trouble in the form of anti-trust lawsuits and investigations for its suppression of generic drugs and fiercely protecting its patents.
Source: Green America (2009)
This company is listed on the Federal Contractor Misconduct Database as having 8 instances of misconduct since 1995 amounting to US$290 million in penalties.
Source: Project on Government Oversight (POGO) (2014)
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Source: We Mean Business (2021)
This company was named in Seramount's 100 Best Companies 2022 for being a mum-friendly employer. Listed companies provide inclusive benefits for families, including paid gender-neutral parental leave, phase-back programs, bereavement leave after miscarriage, reimbursement for fertility expenses, and increased mental health benefits for employees.
Source: Seramount (2022)
This company has a number of corporate responsibility claims and documents on its website.
Source: company website (2020)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
This company received the seventh highest score in the Access to Medicine Index 2018, a ranking of the world's 20 largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
Source: Access to Medicine Index (2018)
|Revenue||45 million USD (2008)|
|Address||Chattanooga, TN, USA|